Scholarlink

Purpose <p>Patients undergoing transurethral prostate surgery often experience catheter-related bladder discomfort (CRBD), which can&#xa0;significantly impairs postoperative recovery. The anatomical convergence between the ilioinguinal and iliohypogastric (II-IH) nerve pathways (T12–L2) and the bladder innervation provides a rationale for&#xa0;evaluating the&#xa0;II-IH nerve block as a potential treatment. This study aimed to investigate the efficacy of ultrasound-guided II-IH nerve block versus intravenous tramadol in reducing postoperative CRBD.</p> Methods <p>Ninety-four patients undergoing transurethral prostate surgery were equally randomized to receive either 1.5&#xa0;mg/kg intravenous tramadol or bilateral ultrasound-guided II-IH nerve block with 15&#xa0;mL of&#xa0;0.375% ropivacaine per side before extubation. Intravenous tramadol was used as rescue medication for moderate-to-severe CRBD. The primary outcome was the overall incidence of CRBD within postoperative 24&#xa0;h. Secondary outcomes included CRBD severity, pain scores, adverse events, patient satisfaction, hospitalization duration, and International Prostate Symptom Scores (IPSSs).</p> Results <p>The overall incidence of CRBD within postoperative 24&#xa0;h was 56.5% in the II-IH block group versus 65.2% in the tramadol group, with an absolute risk difference of −8.70% (95% confidential interval: −24.71% to 10.92%; <i>p</i> = 0.393). Secondary outcomes, including the incidence of moderate-to-severe CRBD, pain scores at all assessed timepoints, rescue tramadol use, length of&#xa0;hospitalization, and IPSSs were comparable between the two&#xa0;groups (all <i>p</i> &gt; 0.05). However, the II-IH block group demonstrated significantly lower incidences of adverse events (including&#xa0;nausea and vomiting, headache, dizziness, and dry mouth) and a&#xa0;higher proportion of extremely satisfied patients (all <i>p</i> &lt; 0.05). Importantly, no nerve block-related complications were observed in the II-IH block group.</p> Conclusions <p>Ultrasound-guided II-IH nerve block appeared to be a comparable alternative to intravenous tramadol for reducing CRBD after transurethral prostate surgery, while offering a more favorable safety profile and higher patient satisfaction.</p> Trial registration <p>Chinese Clinical Trial Registry, ChiCTR2300078552. Registered 12 December 2023, <a href="https://www.chictr.org.cn/showproj.html?proj=209712">https://www.chictr.org.cn/showproj.html?proj=209712</a></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ultrasound-guided ilioinguinal-iliohypogastric nerve block versus intravenous tramadol for preventing catheter-related bladder discomfort after transurethral prostate surgery: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Hongbo Wang,
  • Xianda Zhao,
  • Suwen Hu,
  • Xiyue Zhao,
  • Liangrong Wang

摘要

Purpose

Patients undergoing transurethral prostate surgery often experience catheter-related bladder discomfort (CRBD), which can significantly impairs postoperative recovery. The anatomical convergence between the ilioinguinal and iliohypogastric (II-IH) nerve pathways (T12–L2) and the bladder innervation provides a rationale for evaluating the II-IH nerve block as a potential treatment. This study aimed to investigate the efficacy of ultrasound-guided II-IH nerve block versus intravenous tramadol in reducing postoperative CRBD.

Methods

Ninety-four patients undergoing transurethral prostate surgery were equally randomized to receive either 1.5 mg/kg intravenous tramadol or bilateral ultrasound-guided II-IH nerve block with 15 mL of 0.375% ropivacaine per side before extubation. Intravenous tramadol was used as rescue medication for moderate-to-severe CRBD. The primary outcome was the overall incidence of CRBD within postoperative 24 h. Secondary outcomes included CRBD severity, pain scores, adverse events, patient satisfaction, hospitalization duration, and International Prostate Symptom Scores (IPSSs).

Results

The overall incidence of CRBD within postoperative 24 h was 56.5% in the II-IH block group versus 65.2% in the tramadol group, with an absolute risk difference of −8.70% (95% confidential interval: −24.71% to 10.92%; p = 0.393). Secondary outcomes, including the incidence of moderate-to-severe CRBD, pain scores at all assessed timepoints, rescue tramadol use, length of hospitalization, and IPSSs were comparable between the two groups (all p > 0.05). However, the II-IH block group demonstrated significantly lower incidences of adverse events (including nausea and vomiting, headache, dizziness, and dry mouth) and a higher proportion of extremely satisfied patients (all p < 0.05). Importantly, no nerve block-related complications were observed in the II-IH block group.

Conclusions

Ultrasound-guided II-IH nerve block appeared to be a comparable alternative to intravenous tramadol for reducing CRBD after transurethral prostate surgery, while offering a more favorable safety profile and higher patient satisfaction.

Trial registration

Chinese Clinical Trial Registry, ChiCTR2300078552. Registered 12 December 2023, https://www.chictr.org.cn/showproj.html?proj=209712